Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000434188 | SCV000529334 | uncertain significance | not provided | 2019-06-06 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV001828424 | SCV002792057 | uncertain significance | Polyglandular autoimmune syndrome, type 1 | 2021-10-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001828424 | SCV003451353 | uncertain significance | Polyglandular autoimmune syndrome, type 1 | 2022-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 457 of the AIRE protein (p.Cys457Tyr). This variant is present in population databases (rs373383785, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with AIRE-related conditions. ClinVar contains an entry for this variant (Variation ID: 387341). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AIRE protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001828424 | SCV002076128 | uncertain significance | Polyglandular autoimmune syndrome, type 1 | 2019-10-28 | no assertion criteria provided | clinical testing |